NEW YORK, NY / ACCESSWIRE / September 21, 2018 / Wall Street closed up on Thursday as upbeat economic data and strong corporate earnings helped buoy equities. Unemployment dropped by 3000 to a seasonally adjusted level of 201,000 last week, its lowest since November 1969. The Dow Jones Industrial Average gained 0.95 percent to close at 26,656.98, while the S&P 500 Index hiked 0.78 percent to close at 2,930.75. The Nasdaq Composite Index increased 0.98 percent to close at 8,028.23.
According to Paul Brigandi, managing director and head of trading for Direxion, “Fundamentally and technically, the market is really strong right now. Corporate earnings have been good, and economic data has been really good. At the same time, there’s a sense that China’s most recent trade retaliation wasn’t as severe as expected, which led to some optimism and relief that the situation may not turn into a full-blown trade war.”
RDI Initiates Coverage on:
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals' stock jumped 26.56% Thursday, to close the day at $19.11. The stock recorded a trading volume of 14,998,627 shares, which was above its three months average volume of 2,717,031 shares. In the last year, ACADIA Pharmaceuticals' shares have traded in a range of 12.77 - 41.20. The share price has gained 49.65% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $14.21 is below its 200-day moving average of $17.65. Shares of ACADIA Pharmaceuticals have gained roughly 40.83 percent in the past month and are down 36.53 percent year-to-date.
Access RDI's ACADIA Pharmaceuticals Inc. Research Report at:
On Thursday, shares of BioLineRx recorded a trading volume of 3,374,991 shares, which was above the three months average volume of 276,712 shares. The stock ended the day 16.14% higher at $1.08. The share price has fallen 19.4% from its 52 week high with a 52 week trading range of 0.78 - 1.34. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $0.90 is equal to its 200-day moving average of $0.90. Shares of BioLineRx have gained roughly 21.35 percent in the past month and are down 0.92 percent year-to-date.
Access RDI's BioLineRx Ltd. Research Report at:
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.